OCUGEN INC. - COMMON STOCK

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

26 авг 2024 07:02:41 Источник Nasdaq GlobeNewswire

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

08 авг 2024 06:45:00 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

05 авг 2024 06:30:33 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

02 авг 2024 15:22:33 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

31 июл 2024 21:15:46 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

31 июл 2024 16:15:04 Источник Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

29 июл 2024 07:02:15 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

25 июл 2024 06:30:20 Источник Nasdaq GlobeNewswire

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

21 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

20 июн 2024 06:30:31 Источник Nasdaq GlobeNewswire

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

31 май 2024 08:36:49 Источник Nasdaq GlobeNewswire

Ocugen to Present at BIO International Convention 2024

29 май 2024 07:15:00 Источник Nasdaq GlobeNewswire

Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

28 май 2024 07:02:39 Источник Nasdaq GlobeNewswire

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

20 май 2024 07:00:52 Источник Nasdaq GlobeNewswire

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

15 май 2024 06:30:00 Источник Nasdaq GlobeNewswire

Ocugen Provides Business Update with First Quarter 2024 Financial Results

14 май 2024 08:00:25 Источник Nasdaq GlobeNewswire

Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

10 май 2024 16:05:06 Источник Nasdaq GlobeNewswire

Ocugen to Present at May 2024 Investor Conferences

10 май 2024 07:45:07 Источник Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

03 май 2024 07:30:05 Источник Nasdaq GlobeNewswire

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

02 май 2024 07:15:46 Источник Nasdaq GlobeNewswire